ReviewPharmaceuticals (Basel, Switzerland)2024

Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven.

Sarfaraz K NiaziPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.